Post job

AlloSource main competitors are GenScript, RTI Surgical, and Opti Medical Systems.

Competitor Summary. See how AlloSource compares to its main competitors:

  • Alcon has the most employees (20,001).
  • Employees at GenScript earn more than most of the competitors, with an average yearly salary of $72,821.
Work at AlloSource?
Share your experience

AlloSource vs competitors

CompanyFounding dateZippia scoreHeadquarters# of LocationsRevenueEmployees
1994
4.4
Centennial, CO1$21.4M420
1984
4.7
Kennesaw, GA2$253.2M1,000
1998
4.5
Alachua, FL3$280.0M942
Donor Alliance
1985
3.8
Denver, CO1$37.5M7
-
3.9
Austin, TX1$9.7M175
2002
4.3
Piscataway, NJ1$390.8M3,000
1963
4.7
Durham, NC1-6,828
1958
4.4
San Ramon, CA9$1.1B25
1976
4.6
Waltham, MA2$1.4B3,000
1996
4.7
Lake Zurich, IL2$800.0M72
1869
4.6
Lynchburg, VA1$200.0M750
1982
4.8
Norcross, GA1$380.0M1,125
-
3.9
Mansfield, MA1$790,00025
1870
4.5
Bohemia, NY3$90.6M50
1945
4.8
Fort Worth, TX1$9.9B20,001
2003
4.2
Orlando, FL1$21.0M248
1986
4.5
Roswell, GA1$27.3M105
1985
4.7
Weston, MA9$409.4M1,125
1979
3.8
Kearny, NJ1$132.4M127
2001
4.4
Bloomington, MN1$17.2M50
1839
4.8
Bethlehem, PA4$3.3B4,099

Rate how well AlloSource differentiates itself from its competitors.

Zippia waving zebra

AlloSource salaries vs competitors

Among AlloSource competitors, employees at GenScript earn the most with an average yearly salary of $72,821.

Compare AlloSource salaries vs competitors

CompanyAverage salaryHourly salarySalary score
AlloSource
$48,271$23.21-
CryoLife
$54,541$26.22-
RTI Surgical
$64,097$30.82-
Donor Alliance
$43,810$21.06-
Bioo Scientific
$58,624$28.18-
GenScript
$72,821$35.01-

Compare AlloSource job title salaries vs competitors

CompanyHighest salaryHourly salary
AlloSource
$71,766$34.50
Alcon
$82,421$39.63
CryoLife
$77,686$37.35
RTI Surgical
$77,208$37.12
CooperVision
$74,679$35.90
GenScript
$74,154$35.65
Immucor
$73,102$35.15
Biomérieux
$72,626$34.92
Opti Medical Systems
$72,551$34.88
Bioo Scientific
$72,002$34.62
Pharmachem Laboratories
$71,888$34.56
Sartorius
$71,775$34.51
QTSPackage
$70,878$34.08
Smiths Medical - Wallace
$70,586$33.94
Nova Biomedical
$70,536$33.91
C.B. Fleet
$70,533$33.91
XYMOGEN
$70,477$33.88
Tyco Healthcare
$70,475$33.88
B. Braun Medical
$69,591$33.46
Donor Alliance
$67,301$32.36

Do you work at AlloSource?

Does AlloSource effectively differentiate itself from competitors?

AlloSource jobs

AlloSource demographics vs competitors

Compare gender at AlloSource vs competitors

Job titleMaleFemale
CryoLife41%59%
RTI Surgical54%46%
AlloSource57%43%
Alcon59%41%
B. Braun Medical59%41%
Biomérieux60%40%

Compare race at AlloSource vs competitors

CompanyWhiteHispanic or LatinoBlack or African AmericanAsianUnknownDiversity score
67%16%6%6%5%
8.7
52%11%23%12%3%
9.5
63%14%13%8%3%
7.5
52%20%13%12%4%
9.9
54%21%8%12%4%
9.9
63%11%13%9%4%
9.8

AlloSource and similar companies CEOs

CEOBio
J. Patrick MacKin
CryoLife

Terry Rich
RTI Surgical

Terry Rich works at NUVASIVE INC and a President/CEO at RTI SURGICAL, INC. and Board Member at RTI SURGICAL, INC.. He has worked as Board Member at ALPHATEC HOLDINGS, INC.; Senior VP:Sales at NUVASIVE INC; and President/COO at ALPHATEC HOLDINGS, INC.. Terry attended Rutgers University.

David J. Endicott
Alcon

David J. Endicott is the CEO of Alcon, a member of its Board of Directors, and leads the Alcon Executive Committee. He joined Alcon in July of 2016 as Chief Operating Officer. Prior to Alcon, Mr. Endicott was President of Hospira Infusion Systems, a Pfizer company. During his tenure there, he led Hospira’s medical device business through a turnaround, carve-out, and eventual sale. Critical to the turnaround, he advanced the company’s product pipeline, returned its products to market from quality disruptions and accelerated global growth. Before joining Hospira, David served as an officer and executive committee member of Allergan where he spent more than 25 years of his career in leadership roles across Europe, Asia, Latin America and the US. He accelerated Allergan’s international growth and successfully built new markets focused on medical specialties in the areas of ophthalmology, plastic surgery, dermatology and aesthetic medicine. He currently serves on the Board of Directors of AdvaMed, and has previously served on the Boards of Zeltiq (NASDAQ: ZLTQ), and Orexigen (NASDAQ: OREX). David holds an undergraduate degree in Chemistry from Whitman College, an MBA from the University of Southern California, and is a graduate of the Advanced Management Program at the Harvard Business School.

Jean-Claude Dubacher
B. Braun Medical

Jean-Claude Dubacher is Chairman and CEO of B. Braun of America Inc., which includes B. Braun Medical Inc., B. Braun Interventional Systems, Aesculap® and CAPS®. Mr. Dubacher joined B. Braun in August 2019 as President, B. Braun Medical Inc., and has served as Chairman and Chief Executive Officer of B. Braun Medical Inc. since January 1, 2020. Dubacher’s experience in healthcare spans more than 15 years in consulting and corporate roles including strategy, commercial, supply chain and manufacturing. Prior to joining B. Braun, Dubacher led commercial operations for the Surgical Ophthalmology Division of Johnson & Johnson (formerly Abbott Medical Optics) in Europe. Throughout his career, Mr. Dubacher has demonstrated a passion for focusing on customer needs and supporting people to be successful in developing, manufacturing, marketing, and selling products and services that benefit patients. Dubacher holds a Doctorate Degree in law (Dr. iur.) from the University of Zurich in Switzerland, and an MBA from Harvard Business School. He is a board member for the German American Chamber of Commerce.

Alexandre Mérieux
Biomérieux

John Ducker
Fresenius Kabi

John Ducker is a Plant Manager at Fresenius SE Group, President/CEO at Fresenius Kabi USA, and Director at FRANCESCA'S HOLDINGS CORP. He has worked as Board Member at FRESENIUS KABI ONCOLOGY LIMITED, President/CEO at App Pharmaceuticals Inc., and Board Member at Dabur Pharma Co. Ltd. John studied at University of Cambridge.

Avi Pelossof​
Immucor

Avi Pelossof was appointed Global President of our infectious disease business unit in March 2013, after serving as Vice President of that business from February 2008 to February 2013. Mr. Pelossof joined Alere as Vice President, Blood-Borne Pathogens in January 2007 and served in that role until January 2008. Mr. Pelossof has more than 20 years of experience in diagnostics, global health and international finance, including senior roles at Chembio Diagnostic Systems, a manufacturer of diagnostic tests for infectious diseases, and Citigroup.

Jennifer Prinz
Donor Alliance

Joachim Kreuzburg
Sartorius

AlloSource competitors FAQs

Search for jobs